NASDAQ:EPZM - Epizyme Stock Price, Forecast & News

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Epizyme Inc (NASDAQ:EPZM) announced its quarterly earnings results on Wednesday, October, 30th. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating the Zacks' consensus estimate of ($0.51) by $0.11. The biopharmaceutical company earned $5.72 million during the quarter, compared to the consensus estimate of $5.50 million. Epizyme had a negative net margin of 468.53% and a negative return on equity of 49.38%. View Epizyme's Earnings History.

Epizyme is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Epizyme.

Epizyme issued an update on its third quarter earnings guidance on Wednesday, October, 30th. The company provided earnings per share guidance of -$0.40 for the period, compared to the Thomson Reuters consensus estimate of ($0.48). The company issued revenue guidance of $5.7 million, compared to the consensus revenue estimate of $6.40 million.

8 equities research analysts have issued 1-year price targets for Epizyme's stock. Their forecasts range from $12.00 to $25.00. On average, they expect Epizyme's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price. View Analyst Price Targets for Epizyme.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

Media headlines about EPZM stock have been trending somewhat negative on Sunday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Epizyme earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Epizyme.

Some companies that are related to Epizyme include Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP), Allakos (ALLK), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), FibroGen (FGEN), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), Intercept Pharmaceuticals (ICPT), SAGE Therapeutics (SAGE), Blueprint Medicines (BPMC) and Taro Pharmaceutical Industries (TARO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Synergy Pharmaceuticals (SGYP), Verastem (VSTM), ACADIA Pharmaceuticals (ACAD), Omeros (Omer), Gilead Sciences (Gild), Incyte (INCY), Nektar Therapeutics (NKTR), Array Biopharma (Arry), Insys Therapeutics (INSY) and Karyopharm Therapeutics (KPTI).

Epizyme's stock is owned by a number of of retail and institutional investors. Top institutional investors include Redmile Group LLC (9.48%), State Street Corp (3.14%), Millennium Management LLC (1.29%), Voya Investment Management LLC (0.72%), Rhenman & Partners Asset Management AB (0.49%) and California Public Employees Retirement System (0.30%). Company insiders that own Epizyme stock include David M Mott, Matthew Ros and Robert B Bazemore. View Institutional Ownership Trends for Epizyme.

EPZM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, Redmile Group LLC, Rhenman & Partners Asset Management AB, Teacher Retirement System of Texas, Alps Advisors Inc. and Barclays PLC. Company insiders that have sold Epizyme company stock in the last year include David M Mott, Matthew Ros and Robert B Bazemore. View Insider Buying and Selling for Epizyme.

EPZM stock was purchased by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, California Public Employees Retirement System, Metropolitan Life Insurance Co NY, California State Teachers Retirement System and Zurcher Kantonalbank Zurich Cantonalbank. View Insider Buying and Selling for Epizyme.

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EPZM stock can currently be purchased for approximately $17.71.

Epizyme has a market capitalization of $1.61 billion and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.

The official website for Epizyme is http://www.epizyme.com/.

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]